INTRODUCTION
Complicated skin and soft tissue infections (cSSTIs) are among the most common infections treated in the hospital setting [1, 2] .
They represent the more extreme end of the clinical spectrum of SSTIs [3] as they typically involve deep soft tissue and occur in patients with underlying disease, often requiring intravenous (IV) antibiotic therapy and/or surgical intervention [2] . As a result, their treatment incurs high healthcare costs. cSSTIs frequently complicate clinically significant medical conditions such as peripheral arterial disease, diabetes mellitus or renal insufficiency and can also cause complications in immunocompromised hosts [4] .
Gram-positive pathogens are the predominant cause of cSSTIs. Staphylococcus aureus (S. aureus) was found to be the most frequently occurring pathogen among hospitalized SSTI patients on a global scale in the SENTRY Antimicrobial Surveillance Program [5] , and in a large observational study with 1995 cSSTIs patients hospitalized in Europe [1] .
Antibiotic resistance in isolates from SSTIs has increased significantly over time [6] [7] [8] [9] [10] , but the emergence of meticillin-resistant S. aureus (MRSA) is recognized as the greatest resistance concern [5] , as it complicates the treatment of cSSTIs, limits therapeutic options and impacts treatment outcomes.
Systemic infections with MRSA are associated with a higher mortality rate, a longer length of stay (LOS) in hospital, and greater healthcare costs than non-MRSA infections [11] .
In Greece, where antimicrobial drug resistance rates remain high [12] , MRSA prevalence reaches 40%, which is among the highest in Europe [13] and comparable to figures reported for the USA [14] . The increase in MRSA, in part, reflects the changing epidemiology of soft tissue infections as a consequence of the recent dramatic increase in the incidence of community acquired MRSA (CA-MRSA), the pathogen most commonly isolated from SSTIs in many locations in the US [15] . CA-MRSA strains are distinct from hospital-acquired strains, cause mainly skin and soft tissue infections (ranging in severity from furuncles to necrotizing fasciitis), and are associated with the production of virulence factors like the Panton Valentine Leukocidin (PVL) toxin, which may further complicate treatment [16] . In Europe, the prevalence of infections due to CA-MRSA appear to vary across the continent, with Greece reporting one of the highest rates (30%) of S. aureus infection in outpatients compared to 6-18% in other Western European countries [16, 17] .
Successful management of cSSTI involves prompt recognition, timely surgical debridement or drainage, resuscitation if required and appropriate antibiotic therapy [3] .
Treatment for MRSA-related cSSTIs may include either IV or per os (PO) pharmaceutical treatment for 7-14 days and in most cases hospitalization is required. Vancomycin (VANCO) has historically been the standard of care for MRSA infections, but adverse effects, the need for IV access and growing resistance, tend to limit its use [7] . 
METHODS

Model Overview
A previously published economic model [19] was adapted for the Greek hospital setting, to examine the healthcare resource use and associated economic impact of different management approaches for MRSA-cSSTIs. The model was developed using Microsoft Excel and Visual Basic, and was based on a decision tree for the management of hospitalized patients with MRSA-cSSTIs ( Fig. 1 [20] . For the purpose of the analysis and for simplicity reasons, DAPTO, TIGE and TEICO were also assumed to present equal efficacy rates. Regardless of efficacy assumptions, the adverse event failure rate was calculated as (1-success rate) 9 0.33, assuming 1/3 of treatment failures are due to adverse events and 2/3 are due to lack of efficacy [11] . Patients not cured after receiving first-line antibiotic treatment or who presented with adverse events were assumed to be cured after receiving secondline therapy. The set of patients who discontinued or failed therapy required additional hospitalization days as per the input of the expert panel. As this study was conducted from a hospital perspective, treatment continuation with second-line agents in the outpatient setting was not incorporated into the analysis. Continuation of first-line treatment in the outpatient setting was not taken into consideration due to the fact that the study was conducted from a hospital perspective only. Table 1 . Unit costs for antibiotic agents and inpatient stays are reported in Table 2 .
Model Input Data
Model Outcomes
Inpatient costs consisted of hospitalization, diagnostic/laboratory testing, physician visits Vancomycin IV 1 g (empiric-35%, first line) €8.92 Cheapest generic selected [22] Other IV empiric (daptomycin-26%, Linezolid-14%, teicoplanin-9%, Tigecycline-12%, clindamycin-4%)
€33.89
Average weighted daily cost according to usage % in the Greek hospital setting Daptomycin IV 500 mg €87.50 [22] Linezolid IV 600 mg €37.17 [22] Linezolid PO tab 600 mg €32.80 [22] Tigecycline IV 50 mg €37.10 [22] Teicoplanin IV 400 mg €18.41 [22] DRG diagnosis-related group, IV intravenous, PO per os (orally) 
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RESULTS
Resource Use Pattern
According to the expert panel, MRSA-cSSTI patients in Greece are 56.6% males and most of them are over 60 years of age (57.1%). The current use of the most common antibacterial agents in the management of cSSTIs, as identified by the expert panel, along with an estimated 3-year gradual increase of the cost-saving antibacterial is presented in Table 4 . (current baseline case scenario) to 23% (year 1), to 27% (year 2) and up to 30% (year 3).
Previously conducted studies estimate that 10,287 MRSA-cSSTI patients are treated annually in Greek hospitals [23, 24] . Inputting these figures into the current study model results in potential savings of €193,291 (year 1), €354,798 (year 2) and €347,977 (year 3) compared to the current baseline case scenario, thus a potential saving of €896,065 could be made after 3 years.
Sensitivity Analysis
A series of one-way sensitivity analyses was performed to test the robustness of outcomes and the impact of individual variables on the results. For the baseline case scenario (depicting the current treatment scenario in Greece), LINE was shown to be the most cost-saving first-line antimicrobial agent compared to other treatment options. By extending the scope of its current use (from 19% of patients to a hypothetical 30%), the total (aggregate) budget impact was €896,065 over a 3-year period.
Although LINE drug acquisition cost approximates the average cost of the remaining available treatments for cSSTI, its use may result in significantly reduced medical costs, namely hospitalization costs, compared to other selected antibiotic treatments. Using LOS data from a large phase IV study [20] for the treatment of documented MRSA-cSSTIs, LINE's budget impact savings were further increased to €1,893,600 for the 3-year period (Table 6 ). Clinical data demonstrates 100%
bioavailability [27] of the oral LINE formulation, thus allowing continuation of therapy in both the inpatient and outpatient setting when clinically appropriate and without dosage adjustment.
In addition to reducing LOS and healthcare costs, the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America Guidelines suggest that conversion from parenteral to oral therapy using antimicrobials with excellent bioavailability, when the patient's condition allows, can reduce complications that may arise as a result of IV access. An antimicrobial management program which outlines clinical criteria and guidelines for oral switch could play an important role in safeguarding the balance between incremental antimicrobial acquisition costs and the development of resistance at an institutional level [28] .
Hospitalization has been recognized within international literature as the main cost driver in the treatment of MRSA infections, comprising up to 81% of total treatment costs and making early discharge a reasonable target for savings [29, 30] . A recent retrospective chart review in 12 European countries [26] has shown that by applying early discharge criteria in MRSA-cSSTIs more than one-third of hospitalized patients in usual clinical practice could be discharged from the hospital (37.9% overall and 41.1% for Greece with a mean ± SD potential LOS reduction of 6.2 ± 8.2 and 7.5 ± 10.6 days, respectively).
A treatment strategy that would focus on early discharge followed by outpatient parenteral treatment (OPAT) use or use of orally available antimicrobials could be of benefit. However, OPAT treatment is rather costly and is not commonly used in the Greek NHS setting [31] .
As with every study of this kind, the outcomes must be interpreted in light of a number of limitations. First of all, the study design assumes equal effectiveness among the different treatment schedules. This probably leads to conservative estimations, considering that data from a recent systematic meta-analysis of 14 studies of six antibiotics (n = 1,840) suggested differences in efficacy of different MRSA-cSSTI pharmaceutical treatments [32] , mostly in favor of LINE. The assumption that all patients are cured after receiving second-line treatment and that no patients died represents a simplification of reality. The majority of studies in cSSTIs do report high clinical success and very low mortality rates [15] which are similar for patients treated with LINE or VANCO [20] , however, second-line efficacy data are lacking. All model assumptions were based on a previously published model [19] and were considered reasonable by the panel of experts.
Moreover, the option of outpatient oral and IV treatment continuation was not taken into consideration as this falls beyond the scope of the study (hospital setting). However, this could have a substantial impact on total cost of treatment [33] , especially from an overall healthcare system perspective. Recent evidence shows that the administration of antibacterial treatment administered on an outpatient basis can reduce per patient costs up to 30% [19] .
Another limitation to be considered is the lack of Greek-specific pharmaceutical use and MRSAcSSTI prevalence data. The use of an expert panel approach implies a level of uncertainty with respect to the data acquisition process [34] .
Furthermore, results may not be fully transferable to other treatment settings, as significant variation exists in clinical practice [31] . The actual magnitude of this uncertainty is very difficult to quantify. However, the multidisciplinary make-up of the team of experts and the consistency of estimations produced by expert panels in Greece, as reported by previous research [35] adjusted for inflation in 2012) [25, 26] . Furthermore, as with most pharmacoeconomic studies, drug acquisition costs used in the cost calculations lack consideration for price variation over time.
Notwithstanding its limitations, this study is an illustrative example of the importance of global hospital budget, where higher drug acquisition costs would be offset by the marked reduction in hospital and fixed costs due to early discharge. 
